Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.

Autor: Herling CD; Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, Cologne, Germany., Coombes KR; Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA., Benner A; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Bloehdorn J; Internal Medicine III, University Hospital Ulm, Ulm, Germany., Barron LL; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Abrams ZB; Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA., Majewski T; Department of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bondaruk JE; Department of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bahlo J; Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, Cologne, Germany., Fischer K; Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, Cologne, Germany., Hallek M; Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, Cologne, Germany., Stilgenbauer S; Internal Medicine III, University Hospital Ulm, Ulm, Germany., Czerniak BA; Department of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Oakes CC; Department of Internal Medicine, The Ohio State University, Columbus, OH, USA., Ferrajoli A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Keating MJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Abruzzo LV; Department of Pathology, The Ohio State University, Columbus, OH, USA. Electronic address: lynne.abruzzo@osumc.edu.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2019 Nov; Vol. 20 (11), pp. 1576-1586. Date of Electronic Publication: 2019 Sep 30.

Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways.

Autor: Abruzzo LV; Department of Pathology, The Ohio State University, Columbus, OH, USA lynne.abruzzo@osumc.edu., Herling CD; Department I for Internal Medicine and Center of Integrated Oncology, University of Cologne, Germany., Calin GA; Department of Experimental Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Oakes C; Department of Internal Medicine, The Ohio State University, Columbus, OH, USA., Barron LL; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Banks HE; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Katju V; Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA., Keating MJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Coombes KR; Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.

Publikováno v: Haematologica [Haematologica] 2018 Dec; Vol. 103 (12), pp. 2069-2078. Date of Electronic Publication: 2018 Jul 05.